John Maris is a physician-scientist who has focused for over three decades on the childhood cancer neuroblastoma with the dual goals of improving patient outcomes and also using the disease as a model to understand cancer in general. Trained in molecular genetics, his laboratory has discovered the vast majority of the currently known neuroblastoma susceptibility genes through both family-based and genome-wide association study approaches. His laboratory has also defined the genomic landscape of neuroblastomas at diagnosis and during clonal evolution. These studies have led to the discovery and validation of biomarkers of patient outcomes and novel therapeutic strategies. In parallel, his laboratory has focused on improving neuroblastoma patient outcomes by developing the preclinical rationale and then designing innovative clinical trials for a variety of small molecular, targeted radiotherapeutic, and more recently immunotherapeutic strategies. Dr. Maris has been intimately involved in all aspects of pediatric cancer drug development, and his laboratory has developed multiple collaborations with industry to further speed the process. Finally, Dr. Maris is an internationally recognized practicing pediatric oncologist who cares for children with refractory neuroblastoma from around the world, typically in the context of early phase clinical trials.